Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 132Lymphoid 82Other hematologic neoplasm 23Myeloid 5Genitourinary 4Dermatologic 3Tumor-Agnostic 2Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lenalidomide × Tumor-Agnostic × Clear all
NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
83 enrolled 31 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡